Exploring the Capability and Potential of Genetically Targeted Technology
RNA therapies are a new class of medications that use RNA, a type of genetic material, to treat or prevent diseases. RNA therapies are being developed for a range of conditions, including rare diseases, and are expected to play a key role in the development of new treatments in the future.
Join us for a Capitol Hill breakfast briefing, where we will explore the powerful potential of genetically targeted technology and the profoundly important impact of such RNA-based therapies as antisense oligonucleotides (ASO) and RNAi on treatment and prevention. Panelists will discuss the science behind these therapies, the extraordinary capability they hold to address urgent unmet medical needs, and challenges and opportunities bearing on the future of this transformative area of research & development. Space is limited, so secure your spot today!
When: Wednesday, March 5, 2025 from 8:30am to 10am
Where: Room 2044 Rayburn House Office Building; 45 Independence Ave SW, Washington, DC 20515
Research!America’s “Exploring the Capability and Potential of Genetically Targeted Technology” briefing was supported in part by Alnylam Pharmaceuticals, Eli Lilly and Company, Ionis Pharmaceuticals, and Novartis.